Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Longeveron

Market Cap: US$20.0m

A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.

Aelis Farma

Market Cap: €17.7m

A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders.

Valbiotis

Market Cap: €17.5m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France.

Arecor Therapeutics

Market Cap: UK£14.5m

A biopharmaceutical company, focuses on developing products in diabetes and other indications ion the United Kingdom.

VYNE Therapeutics

Market Cap: US$19.3m

A clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.

X4 Pharmaceuticals

Market Cap: US$19.0m

A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.

Vor Biopharma

Market Cap: US$18.9m

Operates as a clinical-stage cell and genome engineering company.

Q32 Bio

Market Cap: US$18.8m

A clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Cognition Therapeutics

Market Cap: US$18.7m

A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Poolbeg Pharma

Market Cap: UK£14.0m

Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.

HOOKIPA Pharma

Market Cap: US$18.4m

A clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform.

Rubicon Organics

Market Cap: CA$25.5m

Engages in the production, processing, and sale of organic cannabis for the recreational and medical-use markets in Canada and internationally.

Curis

Market Cap: US$17.8m

A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

Nicox

Market Cap: €15.8m

Operates as an ophthalmology company in France and internationally.

Lisata Therapeutics

Market Cap: US$17.7m

A clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Alzinova

Market Cap: SEK 169.4m

A biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden.

Lipocine

Market Cap: US$17.3m

A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders.

NFL Biosciences

Market Cap: €15.3m

A biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers.

SenzaGen

Market Cap: SEK 164.6m

Provides non-animal tests for assessing a substance’s allergenicity.

Oncoinvent

Market Cap: NOK 172.0m

A clinical stage company, develops products to treat cancer patients.

ProMIS Neurosciences

Market Cap: US$16.4m

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.

SAB Biotherapeutics

Market Cap: US$16.0m

A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders.

Unity Biotechnology

Market Cap: US$15.7m

A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

Predilife

Market Cap: €13.8m

Develops and sells medical techniques and mathematical models.

Cocrystal Pharma

Market Cap: US$15.5m

A biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States.

Cingulate

Market Cap: US$15.4m

A biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.

Edesa Biotech

Market Cap: US$15.2m

A clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Calidi Biotherapeutics

Market Cap: US$15.1m

A clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States.

Klaria Pharma Holding AB (publ.)

Market Cap: SEK 144.8m

Operates as a pharmaceutical company.

Moleculin Biotech

Market Cap: US$14.7m

A clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.

BioCardia

Market Cap: US$14.5m

A clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.

Equillium

Market Cap: US$14.3m

A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.

Bolt Biotherapeutics

Market Cap: US$14.2m

A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.

AroCell

Market Cap: SEK 136.8m

A vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden.

Harvard Bioscience

Market Cap: US$13.9m

Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally.

BiomX

Market Cap: US$13.9m

A clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.